Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7946755 | 1.00 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2LMNATDP1DDB1 | |
| SCHEMBL11917928 | 1.00 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2LMNATDP1DDB1 | |
| SCHEMBL8250045 | 0.86 | CRBN (0.33) | CRBN | |
| SCHEMBL7621561 | 0.85 | CA1 (0.35) | ALDH1A1CRBNKMT2A | |
| SCHEMBL18686236 | 0.82 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL20213478 | 0.82 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2LMNATDP1DDB1 | |
| SCHEMBL16097469 | 0.82 | LMNA (0.37) | ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL16097473 | 0.82 | LMNA (0.37) | ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL18943659 | 0.82 | LMNA (0.34) | ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL14415910 | 0.79 | LMNA (0.33) | ALDH1A1SMN1; SMN2LMNACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-9988369-B2 | Heterocyclic triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
| US-20130116445-A1 | TRIAZOLIUM CARBENE CATALYSTS AND PROCESSES FOR ASYMMETRIC CARBON-CARBON BOND FORMATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116445-A1 | TRIAZOLIUM CARBENE CATALYSTS AND PROCESSES FOR ASYMMETRIC CARBON-CARBON BOND FORMATION | TIMCC, CYCS, CTRC | ALDH1A1 4430/4885SMN1; SMN2 3976/4885LMNA 2114/4885 |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, GPR27 | ALDH1A1 2981/4885SMN1; SMN2 4831/4885LMNA 2922/4885 |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, AGTR1 | ALDH1A1 2192/4885SMN1; SMN2 4789/4885LMNA 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.